Business
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of Directors
(TheNewswire) Dr. Daniel Mahony to step down to pursue new commitment LONDON, O...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of Directors \n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Dr.\nDaniel Mahony to step down to pursue new commitment\n \n \n \n \n LONDON, Ontario; BOSTON, Massachusetts – April 22,\n2024 –\n \n \n TheNewswire –\n \n \n \n Sernova Corp. (TSX:SVA) (OTCQB:SEOVF)\n(FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the\ndevelopment of regenerative medicine cell therapies for treatment of\nchronic diseases, announces today that Dr. Bernd Muehlenweg, Senior\nVice President of Global Business Development at Evotec SE (Frankfurt\nStock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO),\nhas been appointed to its Board of Directors.  Evotec recently shared\nthat due to the impending departure of Dr. Daniel Mahony, its current\nSernova Board delegate, who is leaving to pursue a new professional\nundertaking, they would be nominating a new Board representative. \nWith heartfelt gratitude, we wish Dan all the very best in his future\nendeavors.\n \n \n \n Dr. Muehlenweg will join Sernova’s Board of Directors\neffective immediately.  Sernova expects the brief period of overlap\nwith Dr. Daniel Mahony will assist in the transition bringing Dr.\nMuehlenweg rapidly up to speed on Sernova’s operational and\nstrategic matters.\n \n \n \n \n Bernd Muehlenweg's work experience includes various\nsenior leadership positions in the biotech and pharmaceutical industry\nwith a concentration on business development and alliance management\nroles. At Evotec, he leads the company's partnering and out-licensing\nefforts in their focus areas including iPSC-based Cell Therapy,\nPanomics-driven drug discovery, Oncology, Immunology &\nInflammation, Infectious Diseases, Predictive Safety and Enabling\nTechnologies.\n \n \n \n \n Prior to joining Evotec, he held the position of Chief\nBusiness Officer and served on the Executive Board of Nanobiotix, a\nFrench clinical stage oncology company. Bernd co-founded Panoptes\nPharma GmbH, an Austrian biotech company focused on developing\ntherapies for eye diseases, which was later acquired by Eyegate\nPharmaceuticals. Additionally, at Wilex AG, he played a key role in\nthe compan...